2931 - 2940 of 8808 Results
Title
Year
-
OPENTitle: Duration of benefit per Dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®)Journal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 82Issue #:Start Page: 133End Page: 137Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.12.002Best OA location URL: http://www.prd-journal.com/article/S1353802020309007/pdfCitation Count: 5
-
RESTRICTEDTitle: Deciphering the molecular mechanism and crosstalk between Parkinson's disease and breast cancer through multi-omics and drug repurposing approachJournal Name: NeuropeptidesPublisher: Elsevier BVVol: 96Issue #:Start Page: 102283End Page: 102283Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.npep.2022.102283Citation Count: 9
-
RESTRICTEDTitle: Co-registration of Imaging Modalities (MRI, CT and PET) to Perform Frameless Stereotaxic Robotic Injections in the Common MarmosetJournal Name: NeurosciencePublisher: Elsevier BVVol: 480Issue #:Start Page: 143End Page: 154Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.neuroscience.2021.11.009Citation Count: 9
-
RESTRICTEDTitle: Functional Interaction Between α-Synuclein and Nurr1 in Dopaminergic NeuronsJournal Name: NeurosciencePublisher: Elsevier BVVol: 506Issue #:Start Page: 114End Page: 126Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.neuroscience.2022.10.011Citation Count: 1
-
RESTRICTEDTitle: Quantitative Cellular Changes in the Thalamus of Patients with Multiple System AtrophyJournal Name: NeurosciencePublisher: Elsevier BVVol: 459Issue #:Start Page: 142End Page: 152Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.neuroscience.2021.02.003Citation Count: 4
-
RESTRICTEDTitle: Motor Thalamic Deep Brain Stimulation Alters Cortical Activity and Shows Therapeutic Utility for Treatment of Parkinson’s Disease Symptoms in a Rat ModelJournal Name: NeurosciencePublisher: Elsevier BVVol: 460Issue #:Start Page: 88End Page: 106Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.neuroscience.2021.02.019Citation Count: 6
-
OPENTitle: Preserved motor memory in Parkinson's diseaseJournal Name: NeuropsychologiaPublisher: Elsevier BVVol: 167Issue #:Start Page: 108161End Page: 108161Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neuropsychologia.2022.108161Citation Count: 13
-
OPENTitle: Special Issue on new therapeutic approaches to Parkinson diseaseJournal Name: NeuropharmacologyPublisher: Elsevier BVVol: 208Issue #:Start Page: 108998End Page: 108998Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neuropharm.2022.108998Citation Count: 5
-
OPENTitle: Removal of proteinase K resistant αSyn species does not correlate with cell survival in a virus vector-based Parkinson's disease mouse modelJournal Name: NeuropharmacologyPublisher: Elsevier BVVol: 218Issue #:Start Page: 109213End Page: 109213Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.neuropharm.2022.109213Best OA location URL: https://doi.org/10.1016/j.neuropharm.2022.109213Citation Count: 9
-
RESTRICTEDTitle: Combined 5-HT2A and mGlu2 modulation for the treatment of dyskinesia and psychosis in Parkinson's diseaseJournal Name: NeuropharmacologyPublisher: Elsevier BVVol: 186Issue #:Start Page: 108465End Page: 108465Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.neuropharm.2021.108465Citation Count: 17